Eventide Asset Management - Q2 2020 holdings

$4.6 Billion is the total value of Eventide Asset Management's 134 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 0.0% .

 Value Shares↓ Weighting
SRPT  SAREPTA THERAPEUTICS INC$159,699,000
+63.9%
996,0000.0%3.47%
+10.0%
BHVN  BIOHAVEN PHARMACTL HLDG CO L$130,411,000
+114.8%
1,783,7610.0%2.84%
+44.2%
TTD  THE TRADE DESK INC$121,950,000
+110.6%
300,0000.0%2.65%
+41.4%
W  WAYFAIR INCcl a$113,231,000
+269.8%
573,0000.0%2.46%
+148.1%
KRTX  KARUNA THERAPEUTICS INC$100,434,000
+54.8%
901,0770.0%2.18%
+3.9%
CRWD  CROWDSTRIKE HLDGS INCcl a$98,986,000
+80.1%
987,0000.0%2.15%
+20.9%
WCN  WASTE CONNECTIONS INC$75,407,000
+21.0%
804,0000.0%1.64%
-18.8%
LRCX  LAM RESEARCH CORP$65,015,000
+34.8%
201,0000.0%1.41%
-9.5%
ASML  ASML HOLDING N V$63,301,000
+40.7%
172,0000.0%1.38%
-5.6%
MYOK  MYOKARDIA INC$60,001,000
+106.1%
621,0000.0%1.30%
+38.3%
LII  LENNOX INTL INC$59,412,000
+28.2%
255,0000.0%1.29%
-13.9%
GWPH  GW PHARMACEUTICALS PLCads$53,506,000
+40.1%
436,0000.0%1.16%
-5.9%
IPHI  INPHI CORP$52,875,000
+48.4%
450,0000.0%1.15%
-0.4%
BEP  BROOKFIELD RENEWABLE PARTNERpartnership unit$43,886,000
+12.7%
916,2000.0%0.95%
-24.3%
COLL  COLLEGIUM PHARMACEUTICAL INC$42,490,000
+7.2%
2,427,9760.0%0.92%
-28.0%
MNTA  MOMENTA PHARMACEUTICALS INC$40,323,000
+22.3%
1,212,0000.0%0.88%
-17.9%
BPMC  BLUEPRINT MEDICINES CORP$36,036,000
+33.4%
462,0000.0%0.78%
-10.5%
MRTX  MIRATI THERAPEUTICS INC$34,365,000
+48.5%
301,0000.0%0.75%
-0.3%
GBT  GLOBAL BLOOD THERAPEUTICS IN$33,775,000
+23.6%
535,0000.0%0.73%
-17.1%
AVRO  AVROBIO INC$33,248,000
+12.1%
1,905,3070.0%0.72%
-24.7%
PANW  PALO ALTO NETWORKS INC$32,576,000
+40.1%
141,8370.0%0.71%
-6.0%
NOVT  NOVANTA INC$29,896,000
+33.7%
280,0000.0%0.65%
-10.2%
DDOG  DATADOG INC$28,607,000
+141.7%
329,0000.0%0.62%
+62.4%
STSA  SATSUMA PHARMACEUTICALS INC$28,282,000
+37.5%
983,3820.0%0.62%
-7.7%
VCYT  VERACYTE INC$24,087,000
+6.5%
930,0000.0%0.52%
-28.4%
QURE  UNIQURE NV$22,530,000
-5.0%
500,0000.0%0.49%
-36.2%
OKTA  OKTA INCcl a$21,625,000
+63.8%
108,0000.0%0.47%
+9.8%
KALV  KALVISTA PHARMACEUTICALS INC$20,328,000
+58.2%
1,680,0000.0%0.44%
+6.2%
MDB  MONGODB INCcl a$19,465,000
+65.8%
86,0000.0%0.42%
+11.3%
REGN  REGENERON PHARMACEUTICALS$19,271,000
+27.7%
30,9000.0%0.42%
-14.3%
SGEN  SEATTLE GENETICS INC$17,417,000
+47.3%
102,5000.0%0.38%
-1.0%
XPO  XPO LOGISTICS INC$16,995,000
+58.5%
220,0000.0%0.37%
+6.3%
XENE  XENON PHARMACEUTICALS INC$15,977,000
+10.6%
1,274,1000.0%0.35%
-25.9%
PHAT  PHATHOM PHARMACEUTICALS INC$14,809,000
+27.5%
450,0000.0%0.32%
-14.4%
RGEN  REPLIGEN CORP$14,710,000
+28.0%
119,0000.0%0.32%
-14.0%
DCPH  DECIPHERA PHARMACEUTICALS IN$14,512,000
+45.1%
243,0000.0%0.32%
-2.8%
ISRG  INTUITIVE SURGICAL INC$14,246,000
+15.1%
25,0000.0%0.31%
-22.7%
XLRN  ACCELERON PHARMA INC$13,614,000
+6.0%
142,9000.0%0.30%
-28.8%
VRTX  VERTEX PHARMACEUTICALS INC$13,209,000
+22.0%
45,5000.0%0.29%
-18.2%
EPIX  ESSA PHARMA INC$11,840,000
+55.0%
2,010,1690.0%0.26%
+4.0%
ALLK  ALLAKOS INC$11,498,000
+61.5%
160,0000.0%0.25%
+8.2%
MKC  MCCORMICK & CO INC$10,765,000
+27.1%
60,0000.0%0.23%
-14.6%
EIDX  EIDOS THERAPEUTICS INC$10,154,000
-2.7%
213,0000.0%0.22%
-34.6%
GLPG  GALAPAGOS NVspon adr$10,062,000
+0.7%
51,0000.0%0.22%
-32.4%
XNCR  XENCOR INC$9,717,000
+8.4%
300,0000.0%0.21%
-27.2%
ARVN  ARVINAS INC$7,714,000
-16.8%
230,0000.0%0.17%
-44.0%
ETTX  ENTASIS THERAPEUTICS HLDGS I$2,473,000
+16.0%
879,5410.0%0.05%
-21.7%
ZTS  ZOETIS INCcl a$1,946,000
+16.5%
14,2000.0%0.04%
-22.2%
 NEUROCRINE BIOSCIENCES INCnote 2.250% 5/1$1,818,000
+30.0%
1,087,0000.0%0.04%
-11.1%
 SAREPTA THERAPEUTICS INCdbcv 1.500%11/1$882,000
+51.0%
384,0000.0%0.02%0.0%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-08-14
Signatures

The EDGAR filing(s) were signed by:

About Eventide Asset Management

Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.

The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.

The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.

Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.

Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LOWES COS INC40Q3 20233.2%
PALO ALTO NETWORKS INC40Q3 20233.6%
ASML HOLDINGS NV40Q3 20231.9%
NEUROCRINE BIOSCIENCES INC40Q3 20231.1%
REPLIGEN CORP40Q3 20230.5%
VERACYTE INC38Q3 20231.5%
LAM RESEARCH CORP35Q3 20233.4%
XPO LOGISTICS INC34Q1 20233.8%
COLLEGIUM PHARMACEUTICAL INC34Q3 20232.6%
MAGNA INTL INC33Q4 20212.5%

View Eventide Asset Management's complete holdings history.

Latest significant ownerships (13-D/G)
Eventide Asset Management Q2 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cogent Biosciences, Inc.February 14, 20232,589,7783.7%
ESSA Pharma Inc.Sold outFebruary 14, 202300.0%
Freeline Therapeutics Holdings plcFebruary 14, 20235,920,7659.1%
KnowBe4, Inc.Sold outFebruary 14, 202300.0%
Praxis Precision Medicines, Inc.February 14, 20233,518,0627.5%
Prometheus Biosciences, Inc.February 14, 20231,032,9382.2%
SUTRO BIOPHARMA, INC.Sold outFebruary 14, 202300.0%
Vital Farms, Inc.Sold outFebruary 14, 202300.0%
Zymeworks Inc.Sold outFebruary 14, 202300.0%
Entasis Therapeutics Holdings Inc.February 14, 2022590,6021.2%

View Eventide Asset Management's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-20
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Eventide Asset Management's complete filings history.

Compare quarters

Export Eventide Asset Management's holdings